Affinity carrier using mutant VHH antibody
AssigneeJsr Corporation
InventorsYoshihisa Hagihara, Yoko Akazawa, Yuji Ito, Tomonari Matsuda, Norihiko Kiyose, Nobuo Miyazaki, Tetsuo Fukuta, Yusaku Mizuguchi
Life of this patent
Estimating the term…
Abstract
Provision of an affinity carrier using a mutant VHH antibody. An affinity carrier comprising: a solid phase carrier; and an immunoglobulin-binding protein bound to the solid phase carrier; wherein the immunoglobulin-binding protein comprises a mutant VHH antibody or a fragment of the mutant VHH antibody that recognizes an epitope in at least one region selected from the group consisting of amino acids 127 to 184 of SEQ ID NO: 22 and amino acids 13 to 210 of SEQ ID NO: 23.
Claims4
An affinity carrier, comprising:
- a solid phase carrier;
- and
- an immunoglobulin-binding protein bound to the solid phase carrier,
- wherein the immunoglobulin-binding protein comprises a mutant VHH antibody, or a fragment thereof, comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 1, the polypeptide has the CDR1 and CDR2 amino acid sequences of SEQ ID NO:
- 10 and SEQ ID NO:
- 11, respectively, corresponding to amino acids 26 to 35 and 51 to 65 of SEQ ID NO:
- 1, the polypeptide has the CDR3 amino acid sequence of SEQ ID NO:
- 12 corresponding to amino acids 96 to 107 of SEQ ID NO:
- 1, in which at least at one position selected from the group consisting of amino acids 97, 100, and 102 of SEQ ID NO:
- 1 has been substituted with histidine, and the immunoglobulin-binding protein binds to an Fab domain of trastuzumab.
An affinity carrier, comprising:
- a solid phase carrier;
- and
- an immunoglobulin-binding protein bound to the solid phase carrier,
- wherein the immunoglobulin-binding protein comprises a mutant VHH antibody, or a fragment thereof, comprising a polypeptide having at least 90% identity to the amino acid sequence of SEQ ID NO:
- 1, the polypeptide has at least one position selected from the group consisting of amino acids 43, 53, 64, 75, and 86 of SEQ ID NO:
- 1 substituted with arginine and retains the CDR1, CDR2, and CDR3 amino acid sequences of SEQ ID NO:
- 10, SEQ ID NO:
- 11, and SEQ ID NO:
- 12, respectively, corresponding to amino acids 26 to 35, 51-65, and 96-107 of SEQ ID NO:
- 1 except for any substitution at amino acid positions 53 and 64 in CDR2, and the immunoglobulin-binding protein binds to an Fab domain of trastuzumab.
Dependencies are inferred from the claim text.